Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTERNTerns Pharmaceuticals$7.23-2.8%$6.25$1.87▼$10.70$632.71M-0.041.11 million shs1.87 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTERNTerns Pharmaceuticals-2.82%+0.14%+11.40%+86.34%-32.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTERNTerns Pharmaceuticals$7.23-2.8%$6.25$1.87▼$10.70$632.71M-0.041.11 million shs1.87 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTERNTerns Pharmaceuticals-2.82%+0.14%+11.40%+86.34%-32.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTERNTerns Pharmaceuticals 2.60Moderate Buy$15.61115.91% UpsideCurrent Analyst Ratings BreakdownLatest TERN, KZG, JTWO, and VEN2 Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.44(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)Latest TERN, KZG, JTWO, and VEN2 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTERNTerns PharmaceuticalsN/A24.7024.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipTERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableTERN, KZG, JTWO, and VEN2 HeadlinesRecent News About These CompaniesDoing good in people’s lives: Amy Burroughs discusses CMLSeptember 11 at 2:44 PM | pharmaphorum.comPTerns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10 at 1:07 PM | seekingalpha.comTrexquant Investment LP Cuts Stake in Terns Pharmaceuticals, Inc. $TERNSeptember 10 at 3:27 AM | marketbeat.comInvesco Ltd. Raises Holdings in Terns Pharmaceuticals, Inc. $TERNSeptember 10 at 3:03 AM | marketbeat.comObesity Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision ...September 9, 2025 | theglobeandmail.comResearch Analysts Issue Forecasts for TERN Q3 EarningsSeptember 9, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. $TERN Shares Purchased by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comGraham Capital Management L.P. Buys 93,296 Shares of Terns Pharmaceuticals, Inc. $TERNSeptember 8, 2025 | marketbeat.comJump Financial LLC Lowers Stock Holdings in Terns Pharmaceuticals, Inc. $TERNSeptember 8, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for TERN Q3 Earnings?September 8, 2025 | americanbankingnews.comTerns Pharmaceuticals (NASDAQ:TERN) Receives "Neutral" Rating from HC WainwrightSeptember 6, 2025 | marketbeat.comRussell Investments Group Ltd. Has $78,000 Holdings in Terns Pharmaceuticals, Inc. $TERNSeptember 6, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 7% - Here's What HappenedSeptember 4, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar TranscriptSeptember 3, 2025 | seekingalpha.comTerns Pharmaceuticals, Inc. (TERN) Special Call - SlideshowSeptember 3, 2025 | seekingalpha.comDriehaus Capital Management LLC Has $2.11 Million Position in Terns Pharmaceuticals, Inc. $TERNSeptember 3, 2025 | marketbeat.comWellington Management Group LLP Increases Position in Terns Pharmaceuticals, Inc. $TERNSeptember 2, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. $TERN Holdings Boosted by Walleye Capital LLCSeptember 1, 2025 | marketbeat.comNuveen LLC Purchases New Shares in Terns Pharmaceuticals, Inc. $TERNAugust 30, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 30, 2025 | marketbeat.comWeight-Loss Wasteland: 5 Obesity Assets That FailedAugust 25, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmazon’s Chart Just Flashed a Pennant Pattern—Here’s What to DoBy Sam Quirke | August 27, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 20253 Gold ETFs That Could Surge If the Fed Cuts Rates This MonthBy Jordan Chussler | September 1, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025TERN, KZG, JTWO, and VEN2 Company DescriptionsTerns Pharmaceuticals NASDAQ:TERN$7.23 -0.21 (-2.82%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.24 +0.00 (+0.07%) As of 09/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
